Results for the substance vandetanib

Vandetanib is a medication used for the treatment of advanced medullary thyroid carcinoma, a rare form of thyroid cancer. It is a tyrosine kinase inhibitor that targets multiple signaling pathways involved in tumor cell growth and survival, including VEGFR, EGFR, and RET receptors. By blocking these pathways, vandetanib slows tumor progression and can reduce tumor size.

The medication is administered orally, usually once daily, and treatment requires regular monitoring to assess efficacy and manage potential side effects.

Common side effects include diarrhea, nausea, hypertension, skin rashes, and fatigue. In rare cases, severe adverse reactions such as QT interval prolongation, heart failure, or hepatotoxicity may occur.

Vandetanib represents an important therapeutic option for patients with advanced medullary thyroid carcinoma, offering a chance to control disease progression and improve their quality of life.